Tags

Type your tag names separated by a space and hit enter

Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.

Abstract

Chronic hepatitis C (CHC) is one of the most common causes of liver diseases worldwide, affecting 3% of the world population and 3 to 4 million people acquire new infection annually. Despite the recent introduction of novel antiviral drugs for the treatment of CHC, these drugs are expensive and the access to them is not an option for many patients. Hence, the traditional therapy by pegylated interferon-α (Peg-IFN-α) and ribavirin may still have a role in the clinical management of CHC especially in developing countries. However, this standard therapy is associated with several severe extra-hepatic side effects and the most common adverse events are hematological abnormalities and thyroid disorders and they could result in dose reduction and/or termination of therapy. Vitamin D has been shown to be a key regulatory element of the immune system, and its serum concentrations correlate with the severity of liver damage and the development of liver fibrosis/cirrhosis. Furthermore, supplementation with vitamin D with Peg-IFN-α based therapy for the treatment of CHC could be beneficial in increase the response rate to Peg-INF-α based therapy. Vitamin D has also been shown to regulate the thyroid functions and the process of erythropoiesis. This review appraises the data to date researching the role of vitamin D during the treatment of CHC and the potential role of vitamin D in preventing/treating Peg-IFN-α induced thyroiditis and anemia during the course of treatment.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • Authors+Show Affiliations

    ,

    Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University Al Abdeyah, Makkah, PO Box 7607, KSA.

    ,

    Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University Al Abdeyah, Makkah, PO Box 7607, KSA ; Department of Pharmacology, Faculty of Medicine, Assiut University Egypt.

    ,

    Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University Al Abdeyah, Makkah, PO Box 7607, KSA.

    Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University Jeddah, KSA ; Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University Jeddah, Saudi Arabia.

    Source

    Pub Type(s)

    Journal Article
    Review

    Language

    eng

    PubMed ID

    26379820

    Citation

    Refaat, Bassem, et al. "Vitamin D and Chronic Hepatitis C: Effects On Success Rate and Prevention of Side Effects Associated With Pegylated Interferon-α and Ribavirin." International Journal of Clinical and Experimental Medicine, vol. 8, no. 7, 2015, pp. 10284-303.
    Refaat B, El-Shemi AG, Ashshi A, et al. Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin. Int J Clin Exp Med. 2015;8(7):10284-303.
    Refaat, B., El-Shemi, A. G., Ashshi, A., & Azhar, E. (2015). Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin. International Journal of Clinical and Experimental Medicine, 8(7), pp. 10284-303.
    Refaat B, et al. Vitamin D and Chronic Hepatitis C: Effects On Success Rate and Prevention of Side Effects Associated With Pegylated Interferon-α and Ribavirin. Int J Clin Exp Med. 2015;8(7):10284-303. PubMed PMID: 26379820.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin. AU - Refaat,Bassem, AU - El-Shemi,Adel Galal, AU - Ashshi,Ahmed, AU - Azhar,Esam, Y1 - 2015/07/15/ PY - 2015/03/13/received PY - 2015/07/01/accepted PY - 2015/9/18/entrez PY - 2015/9/18/pubmed PY - 2015/9/18/medline KW - Chronic hepatitis C KW - anemia and thyroid disorder KW - pegylated interferon-α KW - vitamin D SP - 10284 EP - 303 JF - International journal of clinical and experimental medicine JO - Int J Clin Exp Med VL - 8 IS - 7 N2 - Chronic hepatitis C (CHC) is one of the most common causes of liver diseases worldwide, affecting 3% of the world population and 3 to 4 million people acquire new infection annually. Despite the recent introduction of novel antiviral drugs for the treatment of CHC, these drugs are expensive and the access to them is not an option for many patients. Hence, the traditional therapy by pegylated interferon-α (Peg-IFN-α) and ribavirin may still have a role in the clinical management of CHC especially in developing countries. However, this standard therapy is associated with several severe extra-hepatic side effects and the most common adverse events are hematological abnormalities and thyroid disorders and they could result in dose reduction and/or termination of therapy. Vitamin D has been shown to be a key regulatory element of the immune system, and its serum concentrations correlate with the severity of liver damage and the development of liver fibrosis/cirrhosis. Furthermore, supplementation with vitamin D with Peg-IFN-α based therapy for the treatment of CHC could be beneficial in increase the response rate to Peg-INF-α based therapy. Vitamin D has also been shown to regulate the thyroid functions and the process of erythropoiesis. This review appraises the data to date researching the role of vitamin D during the treatment of CHC and the potential role of vitamin D in preventing/treating Peg-IFN-α induced thyroiditis and anemia during the course of treatment. SN - 1940-5901 UR - https://www.unboundmedicine.com/medline/citation/26379820/full_citation L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/26379820/ DB - PRIME DP - Unbound Medicine ER -